Construction of a prognostic model of colon cancer patients based on metabolism-related lncRNAs

被引:1
|
作者
Li, Chenyang [1 ]
Liu, Qian [1 ]
Song, Yiran [1 ]
Wang, Wenxin [1 ]
Zhang, Xiaolan [1 ]
机构
[1] Hebei Med Univ, Dept Gastroenterol & Hepatol, Hosp 2, Shijiazhuang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
colon cancer; metabolism; lncNRA; LASSO; prognostic model; EXPRESSION; CELLS;
D O I
10.3389/fonc.2022.944476
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMany studies have shown that metabolism-related lncRNAs may play an important role in the pathogenesis of colon cancer. In this study, a prognostic model for colon cancer patients was constructed based on metabolism-related lncRNAs. MethodsBoth transcriptome data and clinical data of colon cancer patients were downloaded from the TCGA database, and metabolism-related genes were downloaded from the GSEA database. Through differential expression analysis and Pearson correlation analysis, long non-coding RNAs (lncRNAs) related to colon cancer metabolism were obtained. CRC patients were divided into training set and verification set at the ratio of 2:1. Based on the training set, univariate Cox regression analysis was utilized to determine the prognostic differential expression of metabolic-related lncRNAs. The Optimal lncRNAs were obtain by Lasso regression analysis, and a risk model was built to predict the prognosis of CRC patients. Meanwhile, patients were divided into high-risk and low-risk groups and a survival curve was drawn accordingly to determine whether the survival rate differs between the two groups. At the same time, subgroup analysis evaluated the predictive performance of the model. We combined clinical indicators with independent prognostic significance and risk scores to construct a nomogram. C index and the calibration curve, DCA clinical decision curve and ROC curve were obtained as well. The above results were all verified using the validation set. Finally, based on the CIBERSORT analysis method, the correlation between lncRNAs and 22 tumor-infiltrated lymphocytes was explored. ResultsBy difference analysis, 2491 differential lncRNAs were obtained, of which 226 were metabolic-related lncRNAs. Based on Cox regression analysis and Lasso results, a multi-factor prognostic risk prediction model with 13 lncRNAs was constructed. Survival curve results suggested that patients with high scores and have a poorer prognosis than patients with low scores (P<0.05). The area under the ROC curve (AUC) for the 3-year survival and 5-year survival were 0.768 and 0.735, respectively. Cox regression analysis showed that age, distant metastasis and risk scores can be used as independent prognostic factors. Then, a nomogram including age, distant metastasis and risk scores was built. The C index was 0.743, and the ROC curve was drawn to obtain the AUC of the 3-year survival and the 5-year survival, which were 0.802 and 0.832, respectively. The above results indicated that the nomogram has a good predictive effect. Enrichment analysis of KEGG pathway revealed that differential lncRNAs may be related to chemokines, amino acid and sugar metabolism, NOD-like receptor and Toll-like receptor activation as well as other pathways. Finally, the analysis results based on the CIBERSORT algorithm showed that the lncRNAs used to construct the model had a strong polarized correlation with B cells, CD8+T cells and M0 macrophages. Conclusion13 metabolic-related lncRNAs affecting the prognosis of CRC were screened by bioinformatics methods, and a prognostic risk model was constructed, laying a solid foundation for the research of metabolic-related lncRNAs in CRC.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Construction and Assessment of a Prognostic Risk Model for Cervical Cancer Based on Lactate Metabolism-Related lncRNAs
    Gao, Ya
    Liu, Hongyang
    Wan, Junhu
    Chang, Fenghua
    Zhang, Lindong
    Wang, Wenjuan
    Zhang, Qinshan
    Feng, Quanling
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 2943 - 2960
  • [2] Prognosis model of patients with breast cancer based on metabolism-related LncRNAs
    Dan Zhang
    Shiwei Ma
    Liling Yang
    Hongyuan Liu
    Han Jiang
    Yan Wang
    Discover Oncology, 16 (1)
  • [3] A Prognostic Model Based on Metabolism-Related Genes for Patients with Ovarian Cancer
    Dong, Jian
    Zhai, Lianghao
    Gao, Yunge
    Chen, Ligang
    Chen, Biliang
    Lv, Xiaohui
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2023, 510 (01) : 110 - 122
  • [4] A Prognostic Model Based on Metabolism-Related Genes for Patients with Ovarian Cancer
    Dong Jian
    Zhai Lianghao
    Gao Yunge
    Chen Ligang
    Chen Biliang
    Lv Xiaohui
    Doklady Biochemistry and Biophysics, 2023, 510 : 110 - 122
  • [5] Construction and validation of a prognostic model for colon adenocarcinoma based on bile acid metabolism-related genes
    Luo, Qinghua
    Zhou, Ping
    Chang, Shuangqing
    Huang, Zhifang
    Zeng, Xuebo
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [6] Construction and validation of a prognostic model for colon adenocarcinoma based on bile acid metabolism-related genes
    Qinghua Luo
    Ping Zhou
    Shuangqing Chang
    Zhifang Huang
    Xuebo Zeng
    Scientific Reports, 13 (1)
  • [7] Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients
    Huang, Huimin
    Zhou, Shipeng
    Zhao, Xingling
    Wang, Shitong
    Yu, Huajun
    Lan, Linhua
    Li, Liyi
    HELIYON, 2023, 9 (01)
  • [8] Construction and evaluation of a prognostic model based on the expression of the metabolism-related signatures in patients with osteosarcoma
    Tieli Wu
    Xingyi Wu
    BMC Musculoskeletal Disorders, 26 (1)
  • [9] Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer
    Wang, Xiushen
    Pan, Jing
    Guan, Qiutong
    Ren, Ninghui
    Wang, Ping
    Wei, Minjie
    Li, Zhenhua
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma
    Sun, Yimin
    Liu, Bingyan
    Xiao, BaoLai
    Jiang, XueFeng
    Xiang, Jin-Jian
    Xie, Jianping
    Hu, Xiao-Miao
    CANCER MEDICINE, 2023, 12 (05): : 5994 - 6008